Cargando...
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...
Gardado en:
| Publicado en: | Cephalalgia |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7412872/ https://ncbi.nlm.nih.gov/pubmed/32615788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420938652 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|